Physician profile
Michael Barbara
NPI 1376513549
$1,132.12
in general payments reported to CMS, 2019-2025
19 companies · $18.79 in 2025
The $18.79 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $138 · 2023: $67.27 · 2024: $162 · 2025: $18.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160.79 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $150.05 | 2019-2020 | |
| Novo Nordisk INC | $135.16 | 2019-2024 | Rybelsus, Ozempic |
| Gotham Surgical Solutions & Devices, INC. | $110.67 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.72 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $93.45 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $46.90 | 2020-2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $44.29 | 2019-2020 | |
| Astellas Pharma US INC | $43.24 | 2019-2020 | |
| Allergan, INC. | $42.02 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $38.68 | 2019 | |
| Sunovion Pharmaceuticals INC. | $36.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.91 | 2019 | |
| Abbvie INC. | $22.69 | 2024 | |
| Abbott Laboratories | $22.17 | 2024 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $18.79 | 2025 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $18.47 | 2024 | Unithroid |
| Antares Pharma, INC. | $14.14 | 2024 | Xyosted |
| Portola Pharmaceuticals, LLC | $11.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barbara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.